Botanix Pharmaceuticals Limited · ASX:BOT
Botanix Pharmaceuticals — Investor Presentation (March 2019)
20 slides from Botanix Pharmaceuticals's investor presentation, Mar 4, 2019
Slide 1: Updated investor presentation (ASX media release)
ASX/Media Release 4 March 2019 For personal use only Updated investor presentation Philadelphia PA and Sydney Australia, 4 March 2019: Medical dermatology company Botanix Pharmaceuticals (“Botanix” or “the Company”) is pleased to release an updated investor presentation. The presentation will be use
Slide 2: Botanix Overview March 2019
For personal use only Botanix Overview March 2019
Slide 3: 2019 outlook
2019 outlook Transformative year ahead, with planned completion of two Phase 2 studies, a Phase 1b patient study, along with milestones for the broader pipeline and the Permetrex™ technology platform For personal use only Multiple value Data read-outs in 2019 from fully funded clinical studies for p
Slide 4: Clinical programs with near term milestones
Clinical programs with near term milestones Well advanced Phase 2 acne and atopic dermatitis programs as well as Phase 1b psoriasis and pending skin infections clinical programs For personal use only Product candidate Indication Pre-clin Ph 1 Ph 1b Ph 2 Status Phase 1b patient study BTX 1308 Psorias
Slide 5: Permetrex skin delivery technology
Permetrex™ Permetrex™ skin delivery technology Proprietary Permetrex™ technology delivers high doses of drug into the layers of the skin without use of permeation enhancers, preservatives, or irritating levels of alcohol / petrolatum additives For personal use only Unmodified drug With Permetrex™ Dr
Slide 6: BTX 1503 – acne mechanism of action
Acne BTX 1503 – acne mechanism of action BTX 1503 is a safe and well tolerated topical treatment that potentially addresses all of the 3 causes of acne For personal use only BTX 1503 addresses acne pathologies in a CB1/CB2 receptor independent manner1 Cannabidiol has been shown to… Have anti-inflamm
Slide 7: Botanix's acne target market share exceeds US$1.5bn p.a.
Acne Botanix’s acne target market share exceeds US$1.5bn p.a. Competitive products with less ideal safety profiles and potentially poorer efficacy generate more than US$1.5bn per annum between them in revenue For personal use only Top oral brands Top topical brands Revenue Revenue Rank Brands Script
Slide 8: BTX 1503: acne – Phase 2 study well advanced
Acne BTX 1503: acne – Phase 2 study well advanced 12-week randomised, double-blind, vehicle controlled study to evaluate the safety and efficacy of BTX 1503 in patients with moderate to severe acne For personal use only Design Endpoints • 5 dose groups: ~360 subjects • Primary endpoints: • High Dose
Slide 9: Phase 2 patient study advancing on schedule
Acne Phase 2 patient study advancing on schedule All sites are active and recruiting patients, with some Australian sites already reaching maximum recruitment numbers in early 1Q CY2019 For personal use only • No safety issues arising from treated patients to date • Positive feedback from dermatolog
Slide 10: BTX 1204: atopic dermatitis – potential mechanism of action
Atopic dermatitis BTX 1204: atopic dermatitis – potential mechanism of action Atopic dermatitis (and psoriasis) are both T-cell mediated inflammatory diseases of the skin For personal use only Acute phase Chronic phase 1. During the “acute phase”, dendritic cells cause excessive Th2 and Th17 cell ac
Slide 11: Atopic dermatitis – large unmet need for topical drugs
Atopic dermatitis Atopic dermatitis – large unmet need for topical drugs BTX 1204 addresses the need for a safe, non steroid topical option for chronic use with multiple mechanisms of action including anti-inflammatory, anti-microbial and immune modulating For personal use only Projected atopic derm
Slide 12: Phase 1b study results support efficacy and safety potential
Atopic dermatitis Phase 1b study results support efficacy and safety potential BTX 1204 was twice as effective as vehicle (with efficacy still increasing) and displayed a substantial improvement in the key signs of atopic dermatitis1 For personal use only Treatment success (%)2 40% Efficacy still in
Slide 13: BTX 1204: atopic dermatitis – Phase 2 study underway
Atopic dermatitis BTX 1204: atopic dermatitis – Phase 2 study underway 12 week randomised, double-blind, vehicle controlled study to evaluate the safety and efficacy of BTX 1204 in patients with moderate atopic dermatitis (AD) For personal use only Design Endpoints • 2 dose groups: ~200 subjects • P
Slide 14: BTX 1204: atopic dermatitis – Phase 2 study advancing
Atopic dermatitis BTX 1204: atopic dermatitis – Phase 2 study advancing Phase 2 study commenced in late December and targeting top line data in 4Q CY2019 For personal use only • Program leverages existing data from BTX 1503 acne studies, lowering regulatory and safety hurdles • Common DEA licensed d
Slide 15: BTX 1308 for psoriasis
Psoriasis BTX 1308 for psoriasis Phase 1b patient study is testing BTX 1308 in a model that allows biopsies to be collected which will help validate the cannabidiol mechanism of action in skin diseases For personal use only Bioskin GmbH psoriasis plaque model1 Novel multi-drug comparison study forma
Slide 16: BTX 1801: novel antimicrobial for serious skin diseases
Antimicrobial BTX 1801: novel antimicrobial for serious skin diseases Natural potential of cannabinoids is enhanced by delivery with Permetrex™ technology For personal use only Minimum Inhibitory Concentration (MIC) effect of BTX 1801 against industry standard antibiotics 1 BTX 1801 may have the fol
Slide 17: First two targets - for impetigo and bacterial folliculitis
Antimicrobial First two targets - for impetigo and bacterial folliculitis Impetigo and bacterial folliculitis are two of the most common skin infections caused by Staph Aureus bacteria, where bacterial resistance to antibiotics is a growing problem For personal use only Impetigo Bacterial Folliculit
Slide 18: Key catalysts
Key catalysts Significant clinical and operational milestones across multiple programs expected over the next 12 months For personal use only Indicative activities and milestones 1Q CY2019 2Q CY2019 3Q CY2019 4Q CY2019 Upcoming milestones BTX 1308 Phase 1b study in Top line data Psoriasis psoriasis
Slide 19: Disclaimer
Disclaimer For personal use only This presentation prepared by Botanix Pharmaceuticals Limited ("Company") does not constitute, or form part of, an offer to sell or the solicitation of an offer to subscribe for or buy any securities, nor the solicitation of any vote or approval in any jurisdiction,
Slide 20: Contact us
For personal use only Contact us Matt Callahan Botanix Pharmaceuticals Founder and Board Executive Director P: +1 215 767 4184 E: mcallahan@botanixpharma.com Visit us www.botanixpharma.com Follow us on social media Botanix Pharmaceuticals Limited (ASX:BOT) Botanix Overview – March 2019 www.botanixph
Botanix Pharmaceuticals — Investor Presentation (March 2019) on 6ix